Bill Ackman Might Like These Pharma ETFs

Another ETF to consider is the Market Vectors Pharmaceutical ETF (NYSEArca: PPH). Given the recent mergers and acquisitions scuttlebutt in the pharmaceuticals industry, the $309.8 million PPH is an ETF to keep an eye on. The ETF’s combined weight to Allergan and Valeant is 8.7%.

Not only that, but PPH allocates a combined 11.5% of its weight to Pfizer and Astra. Earlier this year, it was reported that Teva Pharmaceuticals (NasdaqGM: TEVA), the world’s largest maker of generic drugs, could be a takeover candidate as well. Teva accounts for nearly 4.8% of PPH’s weight. [Teva Takeover Would Lift This ETF]

At a weight of 3.75%, Allergan is the third-largest holding in the $804.4 million SPDR Pharmaceuticals ETF (NYSEArca: XPH).

Market Vectors Pharmaceutical ETF

Tom Lydon’s clients own shares of Pfizer.